Neurocrine biosciences and xenon pharmaceuticals agrees to develop treatments for epilepsy

Neurocrine biosciences and xenon pharmaceuticals announce agreement to develop treatments for epilepsy.neurocrine biosciences inc - co gains rights to xen901, being developed for treatment of epilepsy.neurocrine biosciences inc - xenon will receive up to $25 million upon fda acceptance of an ind for xen901.neurocrine biosciences - xenon to receive $50 million, including $30 million in cash, $20 million equity investment by co at xenon per share price of $14.196.neurocrine biosciences - under terms of agreement with xenon, co will be responsible for development costs associated with programs.
NBIX Ratings Summary
NBIX Quant Ranking